Biocon targets No.1 global insulin supplier in 5 years

What Biocon is aiming for

Biocon Ltd. says it wants to become the world’s biggest insulin supplier within the next five years, positioning itself to fill a gap as large pharmaceutical companies shift attention to newer diabetes and obesity drugs. In an interview with Bloomberg TV’s Latitude with Haslinda Amin, Biocon co-founder and executive chairperson Kiran Mazumdar-Shaw said, “In five years, we could be the number one insulin company in the world.” She added Biocon is “one of the few companies globally that has the scale to address that opportunity.” The ambition comes at a time when global insulin supply dynamics are being reshaped by investment flowing to next-generation metabolic treatments. Biocon argues that insulin demand remains large and persistent, even as the industry focuses heavily on glucagon-like peptide-1 (GLP-1) therapies.

Biocon’s current position in the insulin market

Mazumdar-Shaw said the Bengaluru-based company is currently the third-largest insulin supplier by volume globally. She also said Biocon has invested “big time” to ramp up production capacity. The company’s strategy is built around continuing to scale conventional insulin manufacturing while many incumbents are redirecting resources elsewhere. Biocon also highlighted its execution track record in insulin supplies. According to the information shared, Biocon has supplied more than 9.2 billion doses of insulin worldwide.

Why Big Pharma’s GLP-1 pivot matters for insulin

Biocon’s plan is tied to what it describes as a shift by long-dominant insulin players toward higher-margin GLP-1 and incretin-based therapies. Novo Nordisk and Eli Lilly, which have been major insulin suppliers, are directing investments into GLP-1 therapies. Sanofi is also cited among large pharmaceutical companies shifting focus and capacity to these newer products. Biocon’s leadership has framed this pivot as leaving a supply gap in conventional insulin formats, particularly in delivery systems beyond basic vials. Mazumdar-Shaw said larger rivals are increasingly switching to insulin in vials as they focus more on GLP-1 opportunities.

Focus on pens and cartridges as others scale back

A key part of Biocon’s positioning is its focus on delivery formats such as pens and cartridges. Mazumdar-Shaw said, “Nobody wants to make insulin in pens and cartridges. We are the only company to make insulin in pens and cartridges,” while describing how large players are prioritising GLP-1 and de-emphasising certain insulin formats. The company is seeking to expand in insulin at a time when it says demand remains high. The strategy is intended to build share not just through volume, but through differentiated delivery formats where competitors may be stepping back.

Capacity expansion and market footprint plans

Biocon has said it plans to expand its insulin market presence across 80 approved markets. It has also stated it is doubling its Malaysia facility’s drug product capacity by FY27. These points underline that Biocon is tying its leadership ambition to manufacturing scale and broader regulatory reach. Alongside the global expansion, the company has also indicated an intent to capture meaningful share of the overall market. Biocon’s CEO and managing director Shreehas Tambe said the company aims to achieve 20 percent market share in the global insulin market within five years.

Biocon’s GLP-1 strategy: selective markets, not India

Even as it doubles down on insulin, Biocon is not ignoring GLP-1 medicines. However, Mazumdar-Shaw said GLP-1 prices are hitting “rock bottom” in India, and she added that Biocon does not plan on selling its generic versions for semaglutide in the country. Instead, Biocon is taking what it describes as a measured approach on GLP-1s by targeting select markets where the opportunity may be better. The geographies mentioned include Canada as well as Latin America, Brazil, the Middle East and Southeast Asia.

Pipeline progress: liraglutide launches and semaglutide filings

Biocon has said it is building its GLP-1 pipeline in parallel with the insulin push. The company has pointed to liraglutide launches in Europe and said semaglutide filings are underway internationally. This dual-track approach is being presented as a way to participate in the growth of newer metabolic therapies without abandoning the large installed base for insulin. The company’s framing is that insulin remains a core, high-volume category, while GLP-1 medicines can be pursued selectively based on pricing and competitive intensity.

US market positioning: interchangeable insulins

Biocon has also highlighted a specific regulatory and commercial advantage in the United States. It said it is the only company in the US with interchangeable versions of both insulin glargine and insulin aspart. Interchangeability allows direct pharmacy-level substitution, which can matter for access, adoption, and scale in a price-sensitive market. The company’s disclosures on interchangeability align with its broader objective of being a high-volume supplier with broad market access. In the context of a global push, US positioning is being used as evidence of regulatory capability and operational scale.

Key facts at a glance

Timeline and capacity milestones mentioned

Market impact: insulin supply focus versus GLP-1 margin chase

The information shared points to a clear split in industry priorities. Biocon is emphasising scale manufacturing of insulin as rivals prioritise GLP-1 therapies where margins are described as higher. At the same time, Biocon is signalling caution in markets where pricing pressure is steep, specifically India for semaglutide generics, where it expects prices to be very low. The company’s stated market choices suggest it is trying to avoid the most aggressive domestic price competition while still building a GLP-1 presence in selected international regions. For investors and industry watchers, the key market variable is whether large suppliers continue to reduce focus on insulin pens and cartridges, which Biocon says creates an opening.

Analysis: why Biocon’s bet is unusual, but grounded in scale

Biocon’s insulin push stands out because the broader narrative in diabetes care is dominated by GLP-1 drugs. Yet the company’s argument is not that GLP-1 is irrelevant; it is that insulin remains essential and large enough to support a leadership bid, especially if major competitors reallocate capacity. The ambition is also being tied to manufacturing steps already described, including capacity investments and the Malaysia expansion by FY27. The company is pairing this with regulatory positioning in the US and expansion across a large number of approved markets. Separately, its refusal to join India’s semaglutide generic price war, as stated by Mazumdar-Shaw, indicates a margin-protection approach rather than a pure volume play in every geography.

Conclusion

Biocon’s leadership has set a clear five-year target: become the world’s top insulin supplier, even as Novo Nordisk, Eli Lilly and Sanofi increasingly prioritise GLP-1 therapies. The company is backing the plan with capacity expansion, a broader market footprint, and continued focus on insulin delivery formats such as pens and cartridges. In parallel, Biocon says it will pursue GLP-1 opportunities selectively outside India, with liraglutide launches in Europe and semaglutide filings underway internationally. The next visible checkpoint mentioned is the planned doubling of drug product capacity at its Malaysia facility by FY27.